Cambridge Major Laboratories and AAIPharma Services Announce Merger
News Oct 03, 2013
Cambridge Major Laboratories, Inc. and AAIPharma Services Corp. have announced their intent to merge to form the premier global supplier of integrated CMC services. Financial terms of the merger were not disclosed.
The merger is expected to close by the end of October 2013, subject to Hart-Scott-Rodino approval and other closing conditions. “The basis for the merger was to start with the right building blocks – a merger of two equals: two highly respected, market-leading firms with proven expertise in API development, analytical chemistry, and finished dosage forms,” said Brian Scanlan, CEO & President of CML. “We believe that we have a strong foundation to deliver superior customer-oriented solutions to expedite drug development and commercialization.”
Scanlan added, “Joining forces to offer a full suite of integrated CMC services delivers meaningful value to customers and the ability to execute with equal strength across API development, analytical services, and finished dosage form manufacturing. The combined CML and AAIPharma will provide a superior customer experience defined by high-quality facilities, best-in-class capabilities, scientific expertise, geographic proximity, and effective support services that maximize scientific and project interaction at each phase.”
”The merger of these two organizations will offer customers a reliable partner that can address the majority of their pharmaceutical development and manufacturing requirements,” stated Patrick Walsh, CEO of AAIPharma Services.
Walsh continued, “The combined organization will provide comprehensive services that include process chemistry, solid state chemistry, API manufacturing, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid and sterile), packaging, and stability services, all supported by robust project management.”
Cannabinoids Are Easier on the Brain Than Booze, Study FindsNews
The research was published in the journal Addiction.READ MORE
Compound Prevents Neurological Damage, Shows Cognitive Benefits in Mouse model of Alzheimer’s DiseaseNews
Mouse nicotinamide riboside study shows potential for human research.READ MORE